View Author
patient cancer study treatment chemotherapy toxicity grade trial nsclc response phase non-small non-small-cell lung cancer stage survival pemetrexed gemcitabine disease oncol cisplatin therapy fitinib ge fitinib cycle radiotherapy month result combination placebo arm b carboplatin response rate tumor group ge fitinib arm agent docetaxel table oncology regimen journal non-small-cell neutropenia study i department induction study ii cell lung cancer placebo arm paclitaxel analysis cohort eortc cancer institute progression etoposide randomized sequential stage iii nsclc phase iii study surmont radiation surgery netherland n 3 disease center erlotinib 3 rd line thrombocytopenia mediastinal number day 1 day 8 disease progression 3–4 maintenance chemoradiotherapy criteria consolidation 1 patient
6 Most Recent Publications
|
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)
(Article)
Gaafar, R.M. Surmont, V. Scagliotti, G.V. Klaveren, R.J. van Papamichael, D. Welch, J.J. Hasan, B. Torri, V. Meerbeeck, J. van |
2011-10-01
|
|
Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: Results from 2 phase I studies
(Article)
Surmont, V. Smit, E.F. Senan, S. Kraaij, C.J. Chouaki, N. Praag, J. Klaveren, R.J. van Jonge, M.J.A. de Aerts, J.G.J.V. Nackaerts, K. Vernhout, R. Gras, J. Wijk, A. van Phernambucq, E.C.J. Meerbeeck, J.P. van |
2010-09-01
|
|
A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer
(Article)
Surmont, V. Aerts, J.G.J.V. Klaveren, R.J. van Tournoy, K. Tan, K.Y. Vernhout, R. Schmitz, P.I.M. Legrand, C. Hoogsteden, H.C. Meerbeeck, J.P. van |
2010-06-01
|
|
Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: A non-randomized phase II study
(Article)
Surmont, V. Aerts, J.G.J.V. Klaveren, R.J. van Pouw, E. Tan, K.Y. Vernhout, R. Gras, J. Salomé, J. Pronk, T. Schmitz, P.I.M. Hoogsteden, H.C. |
2009-12-01
|
|
Non-cross resistant sequential single agent chemotherapy in first-line advanced non-small cell lung cancer patients: Results of a phase II study
(Article)
Surmont, V. Aerts, J.G.J.V. Tan, K.Y. Schramel, F. Vernhout, R. Hoogsteden, H.C. Klaveren, R.J. van |
2009-12-01
|
|
Lessons to learn from EORTC study 08981: A feasibility study of induction chemoradiotherapy followed by surgical resection for stage IIIB non-small cell lung cancer
(Article)
Surmont, V. Klaveren, R.J. van Goor, C. Schramel, F.M.N.H. Manegold, C. Legrand, C. Schil, P.E.Y. van Meerbeeck, J.P. van |
2007-01-01
|
